{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T03:40:52Z","timestamp":1791690052456,"version":"4.3.4"},"reference-count":217,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T00:00:00Z","timestamp":1776556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Neurological and mental disorders are among the main causes of disability worldwide, affecting over three billion people and increasing the socioeconomic burden. Advances in molecular genetics and genome engineering have led to gene-targeted therapies that address root causes rather than just symptoms. This review covers current genome-editing tools, including CRISPR\/Cas, base editing, and prime editing. The focus is on the benefits of gene editing in the central nervous system, where post-mitotic neurons allow lasting effects after a single treatment. It also discusses emerging delivery platforms such as viral vectors, nanoparticles, and exosome systems, as well as methods to bypass the blood\u2013brain barrier. Recent clinical progress in spinal muscular atrophy, Parkinson\u2019s disease, Huntington\u2019s disease, and Alzheimer\u2019s disease is highlighted, with promising preclinical results for autism, bipolar disorder, epilepsy, and other neurogenetic conditions. The review concludes with regulatory issues, market trends, and ongoing clinical trials, underscoring the potential of gene therapies to transform disease management and provide long-term solutions.<\/jats:p>","DOI":"10.3390\/cells15080720","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T12:01:22Z","timestamp":1776686482000},"page":"720","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Gene Editing Strategies for Neurological and Mental Disorders: Advances in Delivery, Methodology, and Clinical Translation"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9425-373X","authenticated-orcid":false,"given":"Amer","family":"Elias","sequence":"first","affiliation":[{"name":"Sagol Department of Neurobiology, Faculty of Natural Sciences, University of Haifa, Haifa 3498838, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2644-7068","authenticated-orcid":false,"given":"Shani","family":"Stern","sequence":"additional","affiliation":[{"name":"Sagol Department of Neurobiology, Faculty of Natural Sciences, University of Haifa, Haifa 3498838, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,19]]},"reference":[{"key":"ref_1","unstructured":"(2026, February 21). Orphanet. Diseases. Available online: https:\/\/www.orpha.net\/en\/disease."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/ajmg.a.61124","article-title":"The burden of rare diseases","volume":"179","author":"Ferreira","year":"2019","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/d41573-019-00180-y","article-title":"How many rare diseases are there?","volume":"19","author":"Haendel","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","article-title":"Estimating cumulative point prevalence of rare diseases: Analysis of the Orphanet database","volume":"28","author":"Nguengang","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13643-026-03094-0","article-title":"Identifying the knowledge needs and preferences of parents of children with rare diseases regarding clinical trials: A scoping review protocol","volume":"15","author":"Mabbott","year":"2026","journal-title":"Syst. Rev."},{"key":"ref_6","unstructured":"NINDS (2026, March 15). Recognizes Rare Disease Day: Shining a Light on the Unknown. National Institute of Neurological Disorders and Stroke, Available online: https:\/\/www.ninds.nih.gov\/news-events\/directors-messages\/all-directors-messages\/ninds-recognizes-rare-disease-day-shining-light-unknown."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41525-024-00396-x","article-title":"Evidence review and considerations for use of first line genome sequencing to diagnose rare genetic disorders","volume":"9","author":"Wigby","year":"2024","journal-title":"npj Genom. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.mito.2021.02.011","article-title":"Ethylmalonic encephalopathy ETHE1 p. D165H mutation alters the mitochondrial function in human skeletal muscle proteome","volume":"58","author":"Sathe","year":"2021","journal-title":"Mitochondrion"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.medj.2020.06.004","article-title":"Fatal perinatal mitochondrial cardiac failure caused by recurrent de novo duplications in the ATAD3 locus","volume":"2","author":"Frazier","year":"2021","journal-title":"Med"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.ajhg.2018.08.013","article-title":"Bi-allelic mutations in NDUFA6 establish its role in early-onset isolated mitochondrial complex I deficiency","volume":"103","author":"Alston","year":"2018","journal-title":"Am. J. Hum. Genet."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"165793","DOI":"10.1016\/j.bbadis.2020.165793","article-title":"Defective proteasome biogenesis into skin fibroblasts isolated from Rett syndrome subjects with MeCP2 non-sense mutations","volume":"1866","author":"Sbardella","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/humu.24135","article-title":"Multiomic analysis elucidates Complex I deficiency caused by a deep intronic variant in NDUFB10","volume":"42","author":"Helman","year":"2021","journal-title":"Hum. Mutat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14789450.2021.1918549","article-title":"Leveraging proteomics in orphan disease research: Pitfalls and potential","volume":"18","author":"Braconi","year":"2021","journal-title":"Expert. Rev. Proteom."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1038\/s41596-020-00462-5","article-title":"Detection of aberrant gene expression events in RNA sequencing data","volume":"16","author":"Mertes","year":"2021","journal-title":"Nat. Protoc."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"15824","DOI":"10.1038\/ncomms15824","article-title":"Genetic diagnosis of Mendelian disorders via RNA sequencing","volume":"8","author":"Kremer","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41525-025-00487-3","article-title":"Review: Utility of mass spectrometry in rare disease research and diagnosis","volume":"10","author":"Zhao","year":"2025","journal-title":"npj Genom. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejpn.2025.03.017","article-title":"Newborn screening for neuro-metabolic disorders: Strategies, clinical benefits, and prerequisites for program expansion","volume":"56","author":"Tuncel","year":"2025","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_18","unstructured":"(2026, March 05). Gene Therapies for Neurological Diseases Report. Available online: https:\/\/beacon-intelligence.com\/market-reports\/gene-therapies-for-neurological-diseases\/."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","article-title":"Global, regional, and national burden of disorders affecting the nervous system, 1990\u20132021: A systematic analysis for the Global Burden of Disease Study 2021","volume":"23","author":"Steinmetz","year":"2024","journal-title":"Lancet Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"the disease course spans 17 to 20 years, chromosomes","volume":"72","author":"MacDonald","year":"1993","journal-title":"Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/13810","article-title":"Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2","volume":"23","author":"Amir","year":"1999","journal-title":"Nat. Genet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1474-4422(15)00044-7","article-title":"Gene hunting in autism spectrum disorder: On the path to precision medicine","volume":"14","author":"Geschwind","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nature20413","article-title":"Decoding ALS: From genes to mechanism","volume":"7628","author":"Taylor","year":"2016","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"a008888","DOI":"10.1101\/cshperspect.a008888","article-title":"Genetics of Parkinson\u2019s Disease","volume":"2","author":"Klein","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.molmed.2025.01.015","article-title":"Gene therapies for neurogenetic disorders","volume":"31","author":"Devinsky","year":"2025","journal-title":"Trends Mol. Med."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Stern, T., Hussein, Y., Cordeiro, D., Sadis, H., Garin-Shkolnik, T., Spiegel, R., Cohen, S., Harari, R., Schlesinger, I., and Stern, S. (2024). Case Report: A Case of a Patient with Smith\u2013Magenis Syndrome and Early-Onset Parkinson\u2019s Disease. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25158447"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.neuron.2011.05.001","article-title":"Adult Neurogenesis in the Mammalian Brain: Significant Answers and Significant Questions","volume":"70","author":"Ming","year":"2011","journal-title":"Neuron"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1126\/sciadv.adl4573","article-title":"Shank3 mutation impairs glutamate signaling and myelination in ASD mouse model and human iPSC-derived OPCs","volume":"10","author":"Fischer","year":"2024","journal-title":"Sci. Adv."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41531-024-00653-x","article-title":"Synaptic dysfunction and extracellular matrix dysregulation in dopaminergic neurons from sporadic and E326K-GBA1 Parkinson\u2019s disease patients","volume":"10","author":"Rosh","year":"2024","journal-title":"npj Park. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"107263","DOI":"10.1016\/j.nbd.2026.107263","article-title":"Brain extracellular matrix implications in multiple neurological disorders revealed through a meta-analysis of transcriptional changes","volume":"219","author":"Sadis","year":"2026","journal-title":"Neurobiol. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41531-022-00366-z","article-title":"Reduced synaptic activity and dysregulated extracellular matrix pathways in midbrain neurons from Parkinson\u2019s disease patients","volume":"8","author":"Stern","year":"2022","journal-title":"npj Park. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41531-024-00715-0","article-title":"Upregulated ECM genes and increased synaptic activity in Parkinson\u2019s human DA neurons with PINK1\/ PRKN mutations","volume":"10","author":"Tripathi","year":"2024","journal-title":"npj Park. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nmeth.3733","article-title":"Editing the epigenome: Technologies for programmable transcription and epigenetic modulation","volume":"13","author":"Thakore","year":"2016","journal-title":"Nat. Methods"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cell.2021.12.021","article-title":"Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins","volume":"185","author":"Banskota","year":"2022","journal-title":"Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41582-020-0373-z","article-title":"CRISPR-based functional genomics for neurological disease","volume":"16","author":"Kampmann","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1172\/JCI92087","article-title":"CRISPR\/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington\u2019s disease","volume":"127","author":"Yang","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Teter, B., Campagna, J., Spilman, P., and John, V. (2025). APOE Gene Editing as a Therapeutic Target Toward Precision Medicine in AD. Apolipoprotein E, Springer.","DOI":"10.1007\/978-3-031-52641-1_73-1"},{"key":"ref_39","first-page":"403","article-title":"Prime Editing of Alzheimer\u2019s Disease High-Risk APOE4 Allele by Brain-Directed Adeno-Associated Virus Vectors","volume":"37","author":"Hackett","year":"2025","journal-title":"Hum. Gene Ther."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Srinivasa, M.A., and Escobar, M. (2025). CRISPR-Based Transcriptional Regulation: Technologies, Applications, and Future Directions. DNA, 5.","DOI":"10.3390\/dna5040057"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Boti, M.A., Diamantopoulos, M.A., and Scorilas, A. (2025). RNA-Targeting Techniques: A Comparative Analysis of Modern Approaches for RNA Manipulation in Cancer Research and Therapeutics. Genes, 16.","DOI":"10.3390\/genes16101168"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1007\/s11033-022-08224-0","article-title":"Effects of combinations of gapmer antisense oligonucleotides on the target reduction","volume":"50","author":"Yanagidaira","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"ref_43","first-page":"1","article-title":"Improved specificity and efficiency of in vivo adenine base editing therapies with hybrid guide RNAs","volume":"2025","author":"Whittaker","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-023-01668-1","article-title":"Multifunctional nanoparticle-mediated combining therapy for human diseases","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_45","first-page":"195","article-title":"Gene therapy for Parkinson\u2019s disease, an update","volume":"8","author":"Axelsen","year":"2018","journal-title":"J. Park. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nature15818","article-title":"Gene therapy returns to centre stage","volume":"526","author":"Naldini","year":"2015","journal-title":"Nature"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.ymthe.2025.03.064","article-title":"AAV vector development, back to the future","volume":"33","author":"Song","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1089\/hum.2020.138","article-title":"Adeno-Associated Virus-Based Gene Therapy for Lifelong Correction of Genetic Disease","volume":"31","author":"Brommel","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics\u2014Developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nrd4310","article-title":"Spanner in the works of filovirus infection","volume":"13","author":"Bray","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/nat.2016.0656","article-title":"Molecular Mechanisms of Antisense Oligonucleotides","volume":"27","author":"Crooke","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s40259-024-00644-7","article-title":"Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases","volume":"38","author":"Chen","year":"2024","journal-title":"Biodrugs"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s43856-023-00419-1","article-title":"Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders","volume":"4","author":"Lauffer","year":"2024","journal-title":"Commun. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nrg2842","article-title":"Genome editing with engineered zinc finger nucleases","volume":"11","author":"Urnov","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1146\/annurev-biochem-010909-095056","article-title":"The discovery of zinc fingers and their applications in gene regulation and genome manipulation","volume":"79","author":"Klug","year":"2010","journal-title":"Annu. Rev. Biochem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3486","article-title":"TALENs: A widely applicable technology for targeted genome editing","volume":"14","author":"Joung","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","article-title":"ZFN, TALEN, and CRIPR\/Cas-based methods for genome engineering","volume":"31","author":"Gaj","year":"2013","journal-title":"Trends Biotechnol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cell.2014.02.001","article-title":"Crystal structure of Cas9 in complex with guide RNA and target DNA","volume":"156","author":"Nishimasu","year":"2014","journal-title":"Cell"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","article-title":"Development and applications of CRISPR-Cas9 for genome engineering","volume":"157","author":"Hsu","year":"2014","journal-title":"Cell"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev.biochem.052308.093131","article-title":"The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway","volume":"79","author":"Lieber","year":"2010","journal-title":"Annu. Rev. Biochem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41576-018-0059-1","article-title":"Base editing: Precision chemistry on the genome and transcriptome of living cells","volume":"19","author":"Rees","year":"2018","journal-title":"Nat. Rev. Genet."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Lu, Y., Bouchard, C., Soucy, N., Siddika, A., Lamothe, G., Godbout, K., and Tremblay, J.P. (2026). The Improvements and Applications of Prime Editing. DNA, 6.","DOI":"10.3390\/dna6010016"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e202500193","DOI":"10.1002\/cbic.202500193","article-title":"The Advancement of Prime Editing Technology","volume":"26","author":"Zhang","year":"2025","journal-title":"ChemBioChem"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"100073","DOI":"10.1016\/j.bidere.2026.100073","article-title":"Prime editing: Emerging mechanisms, engineering innovations, and next-generation applications","volume":"8","author":"Muhammad","year":"2026","journal-title":"BioDesign Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s12276-025-01463-8","article-title":"Emerging trends in prime editing for precision genome editing","volume":"57","author":"Lee","year":"2025","journal-title":"Exp. Mol. Med."},{"key":"ref_70","unstructured":"Prime Medicine Announces (2026, April 10). FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD). Prime Medicine, Inc., 29 April 2024. Available online: https:\/\/investors.primemedicine.com\/news-releases\/news-release-details\/prime-medicine-announces-fda-clearance-investigational-new-drug."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2013.02.022","article-title":"Repurposing CRISPR as an RNA-Guided platform for sequence-specific control of gene expression","volume":"152","author":"Qi","year":"2013","journal-title":"Cell"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/nmeth.3312","article-title":"Highly efficient Cas9-mediated transcriptional programming","volume":"12","author":"Chavez","year":"2015","journal-title":"Nat. Methods"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1126\/science.aaf5573","article-title":"C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector","volume":"353","author":"Abudayyeh","year":"2016","journal-title":"Science"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.cell.2018.02.033","article-title":"Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors","volume":"173","author":"Konermann","year":"2018","journal-title":"Cell"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1126\/science.aaq0180","article-title":"RNA editing with CRISPR-Cas13","volume":"358","author":"Cox","year":"2017","journal-title":"Science"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"102635","DOI":"10.1016\/j.omtn.2025.102635","article-title":"Trends and challenges of AAV-delivered gene editing therapeutics for CNS disorders: Implications for neurodegenerative disease","volume":"36","author":"Kantor","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"102636","DOI":"10.1016\/j.omtn.2025.102636","article-title":"Off-target effects in CRISPR-Cas genome editing for human therapeutics: Progress and challenges","volume":"36","author":"Kalter","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_78","first-page":"1","article-title":"Engineered base editors with reduced bystander editing through directed evolution","volume":"2025","author":"Perrotta","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.cell.2019.01.015","article-title":"Defining the Genetic, Genomic, Cellular, and Diagnostic Architectures of Psychiatric Disorders","volume":"177","author":"Sullivan","year":"2019","journal-title":"Cell"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/s41589-023-01279-5","article-title":"Sniper2L is a high-fidelity Cas9 variant with high activity","volume":"19","author":"Kim","year":"2023","journal-title":"Nat. Chem. Biol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/s41591-018-0137-0","article-title":"A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human haematopoietic stem and progenitor cells","volume":"24","author":"Vakulskas","year":"2018","journal-title":"Nat. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nmeth.4278","article-title":"CIRCLE-seq: A highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets","volume":"14","author":"Tsai","year":"2017","journal-title":"Nat. Methods"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nbt.3117","article-title":"GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases","volume":"33","author":"Tsai","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nmeth.3284","article-title":"Digenome-seq: Genome-wide profiling of CRISPR-Cas9 off-target effects in human cells","volume":"12","author":"Kim","year":"2015","journal-title":"Nat. Methods"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2614125","DOI":"10.1080\/10717544.2026.2614125","article-title":"Non-Viral CRISPR carriers: Transient delivery with lasting effects","volume":"33","author":"Lummerstorfer","year":"2026","journal-title":"Drug Deliv."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e70099","DOI":"10.1111\/cpr.70099","article-title":"CRISPR Technology in Disease Management: An Updated Review of Clinical Translation and Therapeutic Potential","volume":"58","author":"Far","year":"2025","journal-title":"Cell Prolif."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"101536","DOI":"10.1016\/j.omtm.2025.101536","article-title":"Early postnatal expression mitigates immune responses to Cas9 in the murine central nervous system","volume":"33","author":"Hampson","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"172981","DOI":"10.1016\/j.pbb.2020.172981","article-title":"Neuroinflammation in psychiatric disorders: An introductory primer","volume":"196","author":"Dunn","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Toader, C., Serban, M., Munteanu, O., Covache-Busuioc, R.-A., Enyedi, M., Ciurea, A.V., and Tataru, C.P. (2025). From Synaptic Plasticity to Neurodegeneration: BDNF as a Transformative Target in Medicine. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26094271"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Thomson, P.A., Malavasi, E.L.V., Gr\u00fcnewald, E., Soares, D.C., Borkowska, M., and Millar, J.K. (2013). DISC1 genetics, biology and psychiatric illness. Front. Biol., 8.","DOI":"10.1007\/s11515-012-1254-7"},{"key":"ref_91","first-page":"6042132","article-title":"Neural Plasticity during Aging","volume":"2019","author":"Lopera","year":"2019","journal-title":"Neural Plast."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1016\/j.ymthe.2024.11.021","article-title":"Longitudinal imaging of therapeutic enzyme expression after gene therapy for Fabry disease using positron emission tomography and the radiotracer [18F]AGAL","volume":"33","author":"Kaittanis","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s10238-024-01463-4","article-title":"Advances in nucleic acid therapeutics: Structures, delivery systems, and future perspectives in cancer treatment","volume":"24","author":"Zhang","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e1809","DOI":"10.1002\/wnan.1809","article-title":"Nanoparticles for vaccine and gene therapy: Overcoming the barriers to nucleic acid delivery","volume":"14","author":"Smyth","year":"2022","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/hgtb.2015.140","article-title":"Expressing Transgenes That Exceed the Packaging Capacity of Adeno-Associated Virus Capsids","volume":"27","author":"Chamberlain","year":"2016","journal-title":"Hum. Gene Ther. Methods"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2217\/fvl-2017-0011","article-title":"Understanding capsid assembly and genome packaging for adeno-associated viruses","volume":"12","author":"Bennett","year":"2017","journal-title":"Future Virol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1089\/hum.2016.087","article-title":"Adeno-Associated Virus-Based Gene Therapy for CNS Diseases","volume":"27","author":"Hocquemiller","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nrg2971","article-title":"State-of-the-art gene-based therapies: The road ahead","volume":"12","author":"Kay","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.neuron.2019.02.017","article-title":"Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality","volume":"101","author":"Hudry","year":"2019","journal-title":"Neuron"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature14299","article-title":"In vivo genome editing using Staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41434-020-0172-6","article-title":"Maximizing lentiviral vector gene transfer in the CNS","volume":"28","author":"Humbel","year":"2020","journal-title":"Gene Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1042\/BJ20120146","article-title":"Lentiviral vectors: Basic to translational","volume":"443","author":"Sakuma","year":"2012","journal-title":"Biochem. J."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1566523213666131125095046","article-title":"Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy","volume":"13","author":"Wold","year":"2014","journal-title":"Curr. Gene Ther."},{"key":"ref_106","first-page":"GE01","article-title":"Non Viral Vectors in Gene Therapy\u2014An Overview","volume":"9","author":"Ramamoorth","year":"2015","journal-title":"J. Clin. Diagn. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"105834","DOI":"10.1016\/j.ebiom.2025.105834","article-title":"Viral and non-viral vectors in gene therapy: Current state and clinical perspectives","volume":"118","author":"Geng","year":"2025","journal-title":"EBioMedicine"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Seijas, A., Cora, D., Novo, M., Al-Soufi, W., S\u00e1nchez, L., and Arana, \u00c1.J. (2025). CRISPR\/Cas9 Delivery Systems to Enhance Gene Editing Efficiency. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202503.2038.v1"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41573-024-00977-6","article-title":"The 60-year evolution of lipid nanoparticles for nucleic acid delivery","volume":"23","author":"Cullis","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e06812","DOI":"10.1002\/smll.202506812","article-title":"Recent Advances in Lipid Nanoparticles: Nucleic Acid Therapeutics and Targeting Strategies","volume":"21","author":"Sarmah","year":"2025","journal-title":"Small"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"114301","DOI":"10.1016\/j.jconrel.2025.114301","article-title":"Music enhances lipid nanoparticle brain delivery and mRNA transfection in brain cells","volume":"388","author":"Gilon","year":"2025","journal-title":"J. Control. Release"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Amoako, K., Mokhammad, A., Malik, A., Yesudasan, S., Wheba, A., Olagunju, O., Gu, S.X., Yarovinsky, T., Faustino, E.V.S., and Nguyen, J. (2025). Enhancing nucleic acid delivery by the integration of artificial intelligence into lipid nanoparticle formulation. Front. Med. Technol., 7.","DOI":"10.3389\/fmedt.2025.1591119"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"9126","DOI":"10.1007\/s12274-024-6827-7","article-title":"Lipid nanoparticles deliver mRNA to the blood\u2013brain barrier","volume":"17","author":"Kuzminich","year":"2024","journal-title":"Nano Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"eadw0730","DOI":"10.1126\/sciadv.adw0730","article-title":"Lipid nanoparticles for mRNA delivery in brain via systemic administration","volume":"11","author":"Cao","year":"2025","journal-title":"Sci. Adv."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","article-title":"Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases","volume":"235","author":"Saraiva","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Eltaib, L. (2025). Polymeric Nanoparticles in Targeted Drug Delivery: Unveiling the Impact of Polymer Characterization and Fabrication. Polymers, 17.","DOI":"10.3390\/polym17070833"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1039\/D4PM00009A","article-title":"Recent progress on nanosystems for nucleic acid delivery","volume":"1","author":"Walia","year":"2024","journal-title":"RSC Pharm."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.addr.2012.06.014","article-title":"Exosomes as nano-theranostic delivery platforms for gene therapy","volume":"65","author":"Tan","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1146\/annurev-biochem-013118-111902","article-title":"Exosomes","volume":"88","author":"Pegtel","year":"2019","journal-title":"Annu. Rev. Biochem."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"6372","DOI":"10.1126\/science.aan4672","article-title":"Gene therapy comes of age","volume":"359","author":"Dunbar","year":"2018","journal-title":"Science"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"155785","DOI":"10.1016\/j.prp.2024.155785","article-title":"Exosome-mediated delivery of CRISPR-Cas9: A revolutionary approach to cancer gene editing","volume":"266","author":"Balaraman","year":"2025","journal-title":"Pathol. Res. Pract."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1700611","DOI":"10.1002\/advs.201700611","article-title":"Exosome\u2013Liposome Hybrid Nanoparticles Deliver CRISPR\/Cas9 System in MSCs","volume":"5","author":"Lin","year":"2018","journal-title":"Adv. Sci."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12951-023-02259-6","article-title":"Encapsulation and assessment of therapeutic cargo in engineered exosomes: A systematic review","volume":"22","author":"Chen","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"7137","DOI":"10.2147\/IJN.S464249","article-title":"Engineering Exosomes for Therapeutic Applications: Decoding Biogenesis, Content Modification, and Cargo Loading Strategies","volume":"19","author":"Bahadorani","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Onohuean, H., Naik Bukke, S.P., Thalluri, C., Abass, K.S., and Choonara, Y.E. (2025). Exosome engineering for targeted therapy of brain-infecting pathogens: Molecular tools, delivery platforms, and translational advances. Front. Med. Technol., 7.","DOI":"10.3389\/fmedt.2025.1655471"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1186\/s12951-024-02681-4","article-title":"Exosomes as therapeutic and drug delivery vehicle for neurodegenerative diseases","volume":"22","author":"Nouri","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12951-025-03352-8","article-title":"Exosome-powered neuropharmaceutics: Unlocking the blood-brain barrier for next-gen therapies","volume":"23","author":"Mehdizadeh","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1186\/s13287-025-04573-2","article-title":"Intranasal delivery of DPSC-derived small extracellular vesicles-encased phloroglucinol attenuates non-motor and motor deficits and promotes neurogenesis in an in vivo rat model of Parkinson\u2019s disease","volume":"16","author":"Mondal","year":"2025","journal-title":"Stem Cell Res. Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/sctm.18-0162","article-title":"Intranasal Administration of Extracellular Vesicles Derived from Human Teeth Stem Cells Improves Motor Symptoms and Normalizes Tyrosine Hydroxylase Expression in the Substantia Nigra and Striatum of the 6-Hydroxydopamine-Treated Rats","volume":"8","author":"Narbute","year":"2019","journal-title":"Stem Cells Transl. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuroscience.2024.04.010","article-title":"Intranasal Administration of Umbilical Cord Mesenchymal Stem Cell Exosomes Alleviates Parkinson\u2019s Disease","volume":"549","author":"Huang","year":"2024","journal-title":"Neuroscience"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"104","DOI":"10.34172\/bma.29","article-title":"miRNA-Loaded stem cell-derived exosomes in neuroregeneration: Current insights and future perspectives","volume":"2","author":"Ozdemir","year":"2025","journal-title":"Biomed. Adv."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"102715","DOI":"10.1016\/j.omtn.2025.102715","article-title":"miRNAs from mesenchymal-stem-cell-derived extracellular vesicles: Emerging players in regenerative medicine and disease therapy","volume":"36","author":"Shahsavandi","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41419-026-08474-x","article-title":"Extracellular vesicles from stem cells rescue cellular phenotypes and behavioral deficits in SHANK3-associated ASD neuronal and mouse models","volume":"17","author":"Choudhary","year":"2026","journal-title":"Cell Death Dis."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12964-022-00959-4","article-title":"A review on exosomes application in clinical trials: Perspective, questions, and challenges","volume":"20","author":"Rezaie","year":"2022","journal-title":"Cell Commun. Signal."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s13770-021-00361-0","article-title":"Biodistribution of Exosomes and Engineering Strategies for Targeted Delivery of Therapeutic Exosomes","volume":"18","author":"Choi","year":"2021","journal-title":"Tissue Eng. Regen. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"996","DOI":"10.15212\/bioi-2024-0060","article-title":"Advances in Gene Therapy for Neurologic Disorders: An Overview","volume":"6","author":"Chand","year":"2025","journal-title":"BIO Integr."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","article-title":"Strategies for delivering therapeutics across the blood\u2013brain barrier","volume":"20","author":"Terstappen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.cell.2025.12.039","article-title":"AAVLINK: A potent DNA-recombination method for large cargo delivery in gene therapy","volume":"189","author":"Lin","year":"2026","journal-title":"Cell"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1126\/scitranslmed.adn5603","article-title":"Interneuron-specific dual-AAV SCN1A gene replacement corrects epileptic phenotypes in mouse models of Dravet syndrome","volume":"17","author":"Mich","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/nn.4593","article-title":"Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems","volume":"20","author":"Chan","year":"2017","journal-title":"Nat. Neurosci."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.1038\/s41467-024-48974-y","article-title":"Engineering viral vectors for acoustically targeted gene delivery","volume":"15","author":"Li","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s44172-026-00597-5","article-title":"Safe focused ultrasound-mediated blood-brain barrier opening is driven primarily by transient reorganization of tight junctions","volume":"5","author":"Noel","year":"2026","journal-title":"Commun. Eng."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"17742","DOI":"10.1038\/s41598-025-02412-1","article-title":"Aducanumab delivery via focused ultrasound-induced transient blood\u2013brain barrier opening in vivo","volume":"15","author":"Jeong","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"101046","DOI":"10.1016\/j.mam.2021.101046","article-title":"Recent advances, status, and opportunities of magneto-electric nanocarriers for biomedical applications","volume":"83","author":"Kolishetti","year":"2022","journal-title":"Mol. Asp. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s11481-016-9688-3","article-title":"Electro-Magnetic Nano-Particle Bound Beclin1 siRNA Crosses the Blood-Brain Barrier to Attenuate the Inflammatory Effects of HIV-1 Infection in Vitro","volume":"12","author":"Rodriguez","year":"2017","journal-title":"J. Neuroimmune Pharmacol."},{"key":"ref_146","unstructured":"(2026, March 08). Study Details. NCT07448610. Assessing The REAl-World Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated with Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA\u00ae): A U.S. Pragmatic Multicenter Study (STREAM). ClinicalTrial, Available online: https:\/\/clinicaltrials.gov\/study\/NCT07448610?term=Itvisma%20&rank=1."},{"key":"ref_147","unstructured":"(2026, March 09). FDA Approves Gene Therapy for Treatment of Spinal Muscular Atrophy. FDA, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-gene-therapy-treatment-spinal-muscular-atrophy."},{"key":"ref_148","unstructured":"(2026, March 08). Study Details. NCT07081841. AB-1005 Long-Term Follow-Up Study. ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT07081841?term=AB-1005&rank=2."},{"key":"ref_149","unstructured":"(2026, March 08). Study Details. NCT06944522. A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson\u2019s Disease. ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06944522."},{"key":"ref_150","unstructured":"(2026, March 08). Study Details. NCT04120493. Safety and Proof-of-Concept (POC) Study with AMT-130 in Adults with Early Manifest Huntington\u2019s Disease. ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04120493?term=AMT-130&rank=2."},{"key":"ref_151","unstructured":"(2026, March 08). Study Details. NCT05243017. Safety and Efficacy of AMT-130 in European Adults with Early Manifest Huntington\u2019s Disease. ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05243017?term=AMT-130&rank=1."},{"key":"ref_152","unstructured":"(2026, March 17). Study Details. NCT06826612. A Randomized Study of SPK-10001 Gene Therapy in Participants with Huntington\u2019s Disease. ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06826612?cond=huntington%20disease&intr=AAV&rank=3."},{"key":"ref_153","unstructured":"(2026, March 17). Study Details. NCT05541627. A Study to Evaluate AB-1001 Striatal Administration in Adults with Early Manifest Huntington\u2019s Disease. ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05541627?cond=huntington%20disease&intr=AAV&rank=4."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"100150","DOI":"10.1016\/j.tjpad.2025.100150","article-title":"Donanemab: Appropriate use recommendations","volume":"12","author":"Rabinovici","year":"2025","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"102620","DOI":"10.1016\/j.arr.2024.102620","article-title":"Monoclonal therapy with lecanemab in the treatment of mild Alzheimer\u2019s disease: A systematic review and meta-analysis","volume":"104","year":"2025","journal-title":"Ageing Res. Rev."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Katsoulaki, E.E., Dimopoulos, D., and Hadjipavlou-Litina, D. (2025). Multitarget Compounds Designed for Alzheimer, Parkinson, and Huntington Neurodegeneration Diseases. Pharmaceuticals, 18.","DOI":"10.3390\/ph18060831"},{"key":"ref_157","unstructured":"(2026, March 17). Study Details. NCT05400330. Long-Term Follow-Up of Gene Therapy for APOE4 Homozygote Alzheimer\u2019s Disease. ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05400330?intr=LX1001&rank=1."},{"key":"ref_158","unstructured":"(2026, March 11). Study Details. NCT03634007. Gene Therapy for APOE4 Homozygote of Alzheimer\u2019s Disease. ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03634007?cond=alzheimer%27s%20disease&term=APOE2&rank=1."},{"key":"ref_159","unstructured":"(2026, March 09). Gene Therapy for APOE4 Homozygote of Alzheimer\u2019s Disease. TrialScreen. Available online: https:\/\/app.trialscreen.org\/trials\/phase-1-2-alzheimer-disease-gene-therapy-apoe4-homozygote-s-trial-nct03634007."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.1016\/j.ymthe.2024.11.003","article-title":"AAVrh.10 delivery of novel APOE2-Christchurch variant suppresses amyloid and Tau pathology in Alzheimer\u2019s disease mice","volume":"32","author":"Sondhi","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1089\/humc.2017.231","article-title":"AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer\u2019s Disease","volume":"29","author":"Rosenberg","year":"2018","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_162","unstructured":"(2026, March 17). Study Details. NCT05040217. A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer\u2019s Disease and Mild Cognitive Impairment. ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05040217?cond=alzheimer%27s%20disease&intr=AAV&rank=4."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"e101305","DOI":"10.1002\/alz70859_101305","article-title":"A Phase I Clinical Trial of AAV2-BDNF Gene Therapy for Alzheimer\u2019s Disease: Findings","volume":"21","author":"Tuszynski","year":"2025","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41593-023-01499-x","article-title":"Whole-brain in vivo base editing reverses behavioral changes in Mef2c-mutant mice","volume":"27","author":"Li","year":"2024","journal-title":"Nat. Neurosci."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"E4468","DOI":"10.1073\/pnas.1405266111","article-title":"CHD8 regulates neurodevelopmental pathways associated with autism spectrum disorder in neural progenitors","volume":"111","author":"Sugathan","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.cell.2014.06.017","article-title":"Disruptive CHD8 mutations define a subtype of autism early in development","volume":"158","author":"Bernier","year":"2014","journal-title":"Cell"},{"key":"ref_167","unstructured":"Chen, G.T., Nair, G., Osorio, A.J., Holley, S.M., Ghassemzadeh, K., Gonzalez, J., Lu, C., Sanjana, N.E., Cepeda, C., and Geschwind, D.H. (2024). Enhancer-targeted CRISPR-Activation Rescues Haploinsufficient Autism Susceptibility Genes. BioRxiv."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13059-018-1482-5","article-title":"CRISPR-SKIP: Programmable gene splicing with single base editors","volume":"19","author":"Gapinske","year":"2018","journal-title":"Genome Biol."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Savell, K.E., Bach, S.V., Zipperly, M.E., Revanna, J.S., Goska, N.A., Tuscher, J.J., Duke, C.G., Sultan, F.A., Burke, J.N., and Williams, D. (2019). Neuron-Optimized CRISPR\/dCas9 Activation System for Robust and Specific Gene Regulation. ENeuro, 6.","DOI":"10.1101\/371500"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4306\/pi.2010.7.4.243","article-title":"The Role of BDNF as a Mediator of Neuroplasticity in Bipolar Disorder","volume":"7","author":"Grande","year":"2010","journal-title":"Psychiatry Investig."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"e14387","DOI":"10.1111\/acel.14387","article-title":"TMEM16F regulates pathologic \u03b1-synuclein secretion and spread in cellular and mouse models of Parkinson\u2019s disease","volume":"24","author":"Berdichevsky","year":"2025","journal-title":"Aging Cell"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1186\/s13287-021-02585-2","article-title":"In vitro genome editing rescues parkinsonism phenotypes in induced pluripotent stem cells-derived dopaminergic neurons carrying LRRK2 p.G2019S mutation","volume":"12","author":"Chang","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"e79208","DOI":"10.7554\/eLife.79208","article-title":"Highly efficient generation of isogenic pluripotent stem cell models using prime editing","volume":"11","author":"Li","year":"2022","journal-title":"Elife"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1016\/j.cell.2025.06.038","article-title":"In vivo prime editing rescues alternating hemiplegia of childhood in mice","volume":"188","author":"Sousa","year":"2025","journal-title":"Cell"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"e196402","DOI":"10.1172\/JCI196402","article-title":"Base editing rescues seizures and sudden death in a SCN8A mutation-associated developmental epileptic encephalopathy model","volume":"136","author":"Reever","year":"2026","journal-title":"J. Clin. Investig."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/brain\/awx054","article-title":"Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders","volume":"140","author":"Wolff","year":"2017","journal-title":"Brain"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.tins.2018.03.011","article-title":"Progress in Understanding and Treating SCN2A-Mediated Disorders","volume":"41","author":"Sanders","year":"2018","journal-title":"Trends Neurosci."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41586-025-09522-w","article-title":"CRISPR activation for SCN2A-related neurodevelopmental disorders","volume":"646","author":"Tamura","year":"2025","journal-title":"Nature"},{"key":"ref_179","unstructured":"FDA, and CBER (2026, March 10). Considerations for the Use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause. Draft Guidance for Industry, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-use-plausible-mechanism-framework-develop-individualized-therapies-target-specific."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_181","unstructured":"(2026, March 10). FDA Launches Framework for Accelerating Development of Individualized Therapies for Ultra-Rare Diseases. FDA, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-launches-framework-accelerating-development-individualized-therapies-ultra-rare-diseases."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/aor.14503","article-title":"FDA Modernization Act 2.0 allows for alternatives to animal testing","volume":"47","author":"Han","year":"2023","journal-title":"Artif. Organs"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41580-020-0259-3","article-title":"Human organoids: Model systems for human biology and medicine","volume":"21","author":"Kim","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_184","unstructured":"(2026, March 10). Roadmap to Reducing Animal Testing in Preclinical Safety Studies, Available online: https:\/\/www.fda.gov\/files\/newsroom\/published\/roadmap_to_reducing_animal_testing_in_preclinical_safety_studies.pdf."},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Zhao, R., Feng, Q., Xia, Y., Liao, L., and Xie, S. (2025). Iteration of Tumor Organoids in Drug Development: Simplification and Integration. Pharmaceuticals, 18.","DOI":"10.3390\/ph18101540"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s12015-024-10723-5","article-title":"Replacing Animal Testing with Stem Cell-Organoids: Advantages and Limitations","volume":"20","author":"Park","year":"2024","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Xue, C., Sun, F., Zhu, H., Shi, J., Wang, J., Sun, Q., Tong, M., Gu, X., Han, Q., and Shi, W. (Engineering, 2025). Advancements, Strategies, and Challenges in Organoid-Based Drug Evaluation for Tissue Engineering and Regenerative Medicine, Engineering, in press.","DOI":"10.1016\/j.eng.2025.10.013"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.stemcr.2024.04.008","article-title":"Rigor and reproducibility in human brain organoid research: Where we are and where we need to go","volume":"19","author":"Sandoval","year":"2024","journal-title":"Stem Cell Rep."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"105904","DOI":"10.1016\/j.yrtph.2025.105904","article-title":"A call to action: Advancing new approach methodologies (NAMs) in regulatory toxicology through a unified framework for validation and acceptance","volume":"162","author":"Ouedraogo","year":"2025","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Zheng, Y., Zhou, W., Chang, H., and Zheng, K. (2026). Brain organoids as precision models for neurodegenerative diseases: From disease modeling to drug discovery. Front. Neurosci., 20.","DOI":"10.3389\/fnins.2026.1764964"},{"key":"ref_191","unstructured":"(2026, March 10). SECTOR SNAPSHOT. Available online: https:\/\/alliancerm.org\/wp-content\/uploads\/2025\/11\/Sector-Snapshot-Draft-Q3-2025_Published.pdf."},{"key":"ref_192","unstructured":"Armstrong, A. (2026, March 10). Big Pharma Partnerships, Record $22.7B Investment Raise Profile of Regenerative Medicine in 2021. Fierce Biotech, 5 April 2022. Available online: https:\/\/www.fiercebiotech.com\/biotech\/big-pharma-partnerships-record-investment-raise-profile-regenerative-medicine-2021."},{"key":"ref_193","unstructured":"(2026, March 10). Gene, Cell, & RNA Therapy Landscape Report Q4 2025 Quarterly Data Report. Available online: https:\/\/www.asgct.org\/uploads\/files\/general\/Landscape-Report-Q4-2025.pdf."},{"key":"ref_194","unstructured":"(2026, March 10). Digital Health in Neurology Market Size & Share Report 2030. Available online: https:\/\/www.grandviewresearch.com\/industry-analysis\/digital-health-neurology-market-report."},{"key":"ref_195","unstructured":"(2026, March 10). Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results. FirstWord Pharma. Available online: https:\/\/firstwordpharma.com\/story\/7131844."},{"key":"ref_196","unstructured":"(2026, March 10). Gene Therapy Market Worth $36.55 Billion by 2032. Available online: https:\/\/www.marketsandmarkets.com\/PressReleases\/gene-therapy.asp."},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Myrou, A., Barmpagiannos, K., Ioakimidou, A., and Savopoulos, C. (2025). Molecular Biomarkers in Neurological Diseases: Advances in Diagnosis and Prognosis. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202502.0647.v1"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"e000958","DOI":"10.1136\/bmjmed-2024-000958","article-title":"Blood level of neurofilament light chain as a biomarker for neurological disorders","volume":"4","author":"Turner","year":"2025","journal-title":"BMJ Med."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41591-018-0300-7","article-title":"High-performance medicine: The convergence of human and artificial intelligence","volume":"25","author":"Topol","year":"2019","journal-title":"Nat. Med."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.inffus.2018.09.012","article-title":"Machine Learning for Integrating Data in Biology and Medicine: Principles, Practice, and Opportunities","volume":"50","author":"Zitnik","year":"2019","journal-title":"Inf. Fusion"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.30574\/ijsra.2023.8.1.0189","article-title":"Artificial intelligence in multi-omics data integration: Advancing precision medicine, biomarker discovery and genomic-driven disease interventions","volume":"8","author":"Ali","year":"2023","journal-title":"Int. J. Sci. Res. Arch."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13040-024-00391-z","article-title":"Deep learning-based approaches for multi-omics data integration and analysis","volume":"17","author":"Ballard","year":"2024","journal-title":"BioData Min."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41398-025-03573-3","article-title":"Detecting suicide risk in bipolar disorder patients from lymphoblastoid cell lines genetic signatures","volume":"15","author":"Sharma","year":"2025","journal-title":"Transl. Psychiatry"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1038\/s41380-023-02183-z","article-title":"Immunoglobulin genes expressed in lymphoblastoid cell lines discern and predict lithium response in bipolar disorder patients","volume":"28","author":"Mizrahi","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s44360-025-00002-z","article-title":"Artificial intelligence and the future of evidence-based medicine","volume":"1","author":"Wong","year":"2026","journal-title":"Nat. Health"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"fcae265","DOI":"10.1093\/braincomms\/fcae265","article-title":"Integrative approach of omics and imaging data to discover new insights for understanding brain diseases","volume":"6","author":"Yoon","year":"2024","journal-title":"Brain Commun."},{"key":"ref_207","first-page":"185","article-title":"The Impact of Artificial Intelligence in Gene Therapy","volume":"2024","author":"Greeshma","year":"2024","journal-title":"Int. J. Sci. Res. Technol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4274\/balkanmedj.galenos.2024.2024-080824","article-title":"Integration of Artificial Intelligence and Genome Editing System for Determining the Treatment of Genetic Disorders","volume":"41","year":"2024","journal-title":"Balk. Med. J."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"102691","DOI":"10.1016\/j.omtn.2025.102691","article-title":"Advancing CRISPR with deep learning: A comprehensive review of models and databases","volume":"36","author":"Alipanahi","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"100920","DOI":"10.1016\/j.medj.2025.100920","article-title":"Challenges and opportunities in the network medicine of complex diseases","volume":"7","author":"Loscalzo","year":"2026","journal-title":"Med"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1016\/j.cell.2023.07.039","article-title":"Phage-assisted evolution and protein engineering yield compact, efficient prime editors","volume":"186","author":"Doman","year":"2023","journal-title":"Cell"},{"key":"ref_212","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Gonz\u00e1lez, N., Gon\u00e7alves-S\u00e1nchez, J., G\u00f3mez-Nieto, R., Gon\u00e7alves-Estella, J.M., and L\u00f3pez, D.E. (2024). Advances and Challenges in Gene Therapy for Neurodegenerative Diseases: A Systematic Review. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252312485"},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Zhang, X., Zhang, R., Nisa Awan, M.U., and Bai, J. (2022). The Mechanism and Function of Glia in Parkinson\u2019s Disease. Front. Cell. Neurosci., 16.","DOI":"10.3389\/fncel.2022.903469"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"105015","DOI":"10.1016\/j.nbd.2020.105015","article-title":"The role of glia in protein aggregation","volume":"143","author":"Li","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"ref_215","first-page":"157","article-title":"Recent advances in gene therapy for lysosomal storage disorders","volume":"8","author":"Rastall","year":"2015","journal-title":"Appl. Clin. Genet."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s13311-019-00782-9","article-title":"Cell-Autonomous and Non-Cell-Autonomous Pathogenic Mechanisms in Huntington\u2019s Disease: Insights from In Vitro and In Vivo Models","volume":"16","author":"Ehrlich","year":"2019","journal-title":"Neurotherapeutics"},{"key":"ref_217","unstructured":"FDA, and CBER (2026, April 14). Human Gene Therapy for Neurodegenerative Diseases; Guidance for Industry, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/human-gene-therapy-neurodegenerative-diseases."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/8\/720\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:43:15Z","timestamp":1777354995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/8\/720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,19]]},"references-count":217,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["cells15080720"],"URL":"https:\/\/doi.org\/10.3390\/cells15080720","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,19]]}}}